Andrew Zloza, MD, PhD, is the Section Chief of Surgical Oncology Research and a member of the Clinical Investigations and Precision Therapeutics Program at Rutgers Cancer Institute of New Jersey (CINJ). He is also an Assistant Professor in the Department of Surgery at Rutgers Robert Wood Johnson Medical School and the founding Faculty Director of the Immune Monitoring Core at Rutgers CINJ.
Dr. Zloza's laboratory focuses on defining the effects of infections (exogenous viral and bacterial, endogenous retroviral, and modified oncolytic) on anti-cancer immune responses. Towards this effort he has successfully developed a double-humanized patient-derived xenograft model that allows for in vivo studies of a patient's anti-cancer immune response in the context of that patient's intact tumor microenvironment. His long-term goals are to utilize patient infectious disease histories towards discovering new cancer immunotherapies and developing a unified theory of infection, cancer, and autoimmunity.